About Us
We are a team of passionate entrepreneurs reinventing drug development
We are a team of passionate entrepreneurs reinventing drug development
Despite the initial benefit from tyrosine kinase inhibitors (TKIs) targeting oncogenic ALK and ROS1 gene fusions in non-small cell lung cancer, complete responses are rare…
Despite the initial benefit from tyrosine kinase inhibitors (TKIs) targeting oncogenic ALK and ROS1 gene fusions in non-small cell lung cancer, complete responses are rare…
Despite the initial benefit from tyrosine kinase inhibitors (TKIs) targeting oncogenic ALK and ROS1 gene fusions in non-small cell lung cancer, complete responses are rare…
ResearchIn-Press PreviewOncology Open Access | 10.1172/jci.insight.173688 Takahiro Utsumi,1 Yuki Shimizu,1 Ai Takemoto,1 Tomoko Oh-hara,1 Ken Uchibori,2 Sophia Subat-Motoshi,3 Hironori Ninomiya,3 Kengo Takeuchi,4 Makoto Nishio,2 Yasunari…
Rearrangements of the ALK gene have been associated with sensitivity to crizotinib and other kinase inhibitors with activity against ALK. The phase III PROFILE 1007…
Abstract. Despite the initial benefit from tyrosine kinase inhibitors (TKIs) targeting oncogenic ALK and ROS1 gene fusions in non-small cell lung cancer, complete responses are…
CRISPR/Cas9 gene editing represents a powerful tool for investigating fusion oncogenes in cancer biology. Successful experiments require that sgRNAs correctly associate with their target sequence…
National DNA Day commemorates the successful completion of the Human Genome Project in 2003 and the discovery of DNA’s double helix in 1953.
PurposeGene fusions involving receptor tyrosine kinases (RTKs) define an important class of genomic alterations with many successful targeted therapies now approved for ALK, ROS1, RET…